Registry of Minimally Invasive Cancer Treatment Using Spectral Angio-CT Image Guidance
PreciseOnco
Prospective Registry of Spectral Angio-CT-Guided Interventional Oncology Procedures in Routine Clinical Practice
1 other identifier
observational
2,000
2 countries
3
Brief Summary
This study collects data from patients undergoing minimally invasive, image-guided cancer treatments at participating hospitals in the Netherlands and France. All treatments are performed as standard clinical care and include procedures such as tumor ablation and catheter-based treatments of cancer in the liver, kidney, lung, and bone. During these procedures, a spectral angio-CT system is used for image guidance. This advanced CT scanner automatically captures additional imaging information beyond what is used in routine clinical decision-making. The goal of this study is to investigate how this additional imaging information is associated with treatment outcomes, and how it can be used in the future to improve treatment planning, procedural guidance, and prediction of treatment results. No experimental interventions are performed. Participation does not alter the treatment or follow-up patients receive. Data are collected from medical records and imaging systems and stored securely for analysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2026
Longer than P75 for all trials
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 28, 2026
CompletedFirst Posted
Study publicly available on registry
June 9, 2026
CompletedStudy Start
First participant enrolled
July 1, 2026
ExpectedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2030
Study Completion
Last participant's last visit for all outcomes
December 31, 2030
June 9, 2026
June 1, 2026
4.5 years
May 28, 2026
June 3, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Local tumor control
Local tumor control at the treated site, assessed at 6 months, 1 year, 2 years, and 3 years after the procedure.
6 months, 1 year, 2 years, 3 years
Secondary Outcomes (5)
Overall survival
6 months, 1 year, 2 years, 3 years
Progression-free survival
6 months, 1 year, 2 years, 3 years
Ablation margin and embolization completeness
At time of procedure
Incidence of periprocedural adverse events
30 days after procedure
Procedure duration
At time of procedure
Eligibility Criteria
Adult patients (18 years or older) with solid tumors undergoing clinically indicated minimally invasive cancer treatments at participating centers in the Netherlands and France. Eligible procedures include percutaneous techniques such as thermal ablation, and catheter-based approaches such as transarterial embolization, chemoembolization, and radioembolization, for tumors in organs including the liver, kidney, lung, and musculoskeletal system. The spectral angio-CT must be used as part of standard clinical care during the procedure. Patients who are incapacitated or have psychiatric disorders precluding informed consent are excluded.
You may qualify if:
- Age ≥ 18 years;
- Undergoing a clinically indicated IO procedure with a percutaneous or transarterial approach for solid tumors;
- Use of spectral angio-CT image guidance as part of standard care;
- Written confirmed consent.
You may not qualify if:
- Patients who are declared incapacitated;
- Patients suffering from psychic disorders that make a comprehensive judgement impossible.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mark C Burgmans, MD PhDlead
- European Commissioncollaborator
- Philips Medical Systemscollaborator
- Philips Electronics Nederland BVcollaborator
- Philips France Commercialcollaborator
- Philips GmbH Innovate Technologiescollaborator
- Quantum Surgicalcollaborator
- IGEAcollaborator
- Hospices Civils de Lyoncollaborator
- Assistance Publique - Hôpitaux de Pariscollaborator
- EIBIR - European Institute for biomedical imaging researchcollaborator
- Cardiovascular and Interventional Radiological Society of Europecollaborator
- Klinikum der Universität zu Köln, Institut für Klinische Chemiecollaborator
Study Sites (3)
Hospices Civils de Lyon - Hôpital Édouard Herriot
Lyon, Auvergne-Rhône-Alpes, 69002, France
Assistance Publique Hopitaux de Paris - Hôpital Henri Mondor
Créteil, Île-de-France Region, 94000, France
Leiden University Medical Center
Leiden, South Holland, 2333 ZA, Netherlands
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 3 Years
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Prof. Dr. Mark C. Burgmans
Study Record Dates
First Submitted
May 28, 2026
First Posted
June 9, 2026
Study Start (Estimated)
July 1, 2026
Primary Completion (Estimated)
December 31, 2030
Study Completion (Estimated)
December 31, 2030
Last Updated
June 9, 2026
Record last verified: 2026-06